相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Felix Friedrich Reichel et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2023)
Therapy with voretigene neparvovec. How to measure success?
Krunoslav Stingl et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2023)
Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec
Krunoslav Stingl et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2022)
Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy
Line Kessel et al.
OPHTHALMOLOGY (2022)
Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis
William S. Gange et al.
OPHTHALMOLOGY RETINA (2022)
AAV cis-regulatory sequences are correlated with ocular toxicity
Wenjun Xiong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy Results of Phase 1 and 3 Trials
Albert M. Maguire et al.
OPHTHALMOLOGY (2019)
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Stephen Russell et al.
LANCET (2017)
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
Albert M. Maguire et al.
LANCET (2009)
The Rpe65 Leu450Met variation increases retinal resistance against light-induced degeneration by slowing rhodopsin regeneration
A Wenzel et al.
JOURNAL OF NEUROSCIENCE (2001)